How Does It Work?
Schedule a Demo
Interested in how iDose can improve your patient outcomes?
Diane R. Mould, PhD
Dr. Diane R. Mould, Chief Scientific Officer (CSO) of Baysient, discusses individual variability in infliximab excretion and elimination. The variations seen in the individual pharmacokinetics of biologics highlight the need for more prospective data to further support effective personalized dosing. By focusing on important, modifiable factors for regulating drug levels, we can improve the efficacy of inflammatory disease treatments in clinical settings.
Latest Blog Post
Inflammatory Bowel Disease (IBD) presents a significant treatment challenge for gastroenterologists worldwide. While biologic therapies have emerged as a cornerstone in managing these complex gastrointestinal conditions, their effectiveness is often hampered by a crucial factor – the variable clearance of biologic drugs from the patient’s…